Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37022706

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2023 Jun 1
First author
Harrington KJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2023 Jun 1;9(6):789-790. doi: 10.1001/jamaoncol.2023.0086.
    note
    Source null
    related pmid
    37022697
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2024 Jan 1;10(1):143-144. doi: 10.1001/jamaoncol.2023.5404.
    note
    Source null
    related pmid
    37991743
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2024 Jan 1;10(1):142-143. doi: 10.1001/jamaoncol.2023.5401.
    note
    Source null
    related pmid
    37991750
    relationship
    Comment in

Authors and identifiers

  1. name
    Harrington KJ
    type
    Author
  2. name
    Ferris RL
    type
    Author
  3. name
    Gillison M
    type
    Author
  4. name
    Tahara M
    type
    Author
  5. name
    Argiris A
    type
    Author
  6. name
    Fayette J
    type
    Author
  7. name
    Schenker M
    type
    Author
  8. name
    Bratland Å
    type
    Author
  9. name
    Walker JWT
    type
    Author
  10. name
    Grell P
    type
    Author
  11. name
    Even C
    type
    Author
  12. name
    Chung CH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Harrington KJ
    type
    Author
  2. name
    Ferris RL
    type
    Author
  3. name
    Gillison M
    type
    Author
  4. name
    Tahara M
    type
    Author
  5. name
    Argiris A
    type
    Author
  6. name
    Fayette J
    type
    Author
  7. name
    Schenker M
    type
    Author
  8. name
    Bratland Å
    type
    Author
  9. name
    Walker JWT
    type
    Author
  10. name
    Grell P
    type
    Author
  11. name
    Even C
    type
    Author
  12. name
    Chung CH
    type
    Author
bibliography ids
  1. nci-bib-efc15b6936e35308a4d9f349
book metadata
content sha256
53457a821eba329763cc1781824284a9a306e607bbf4596c62dcf3041efd100b
document type
citation
dois
  1. 10.1001/jamaoncol.2023.0147
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:37022706
immutable id
pubmed:37022706@53457a821eba329763cc1781824284a9a306e607bbf4596c62dcf3041efd100b
journal
abbreviation
JAMA Oncol
issn electronic
2374-2445
issn print
2374-2437
issue
6
name
JAMA oncology
nlm unique id
101652861
pages
779-789
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2023 Jun 1;9(6):789-790. doi: 10.1001/jamaoncol.2023.0086.
    note
    Source null
    related pmid
    37022697
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2024 Jan 1;10(1):143-144. doi: 10.1001/jamaoncol.2023.5404.
    note
    Source null
    related pmid
    37991743
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2024 Jan 1;10(1):142-143. doi: 10.1001/jamaoncol.2023.5401.
    note
    Source null
    related pmid
    37991750
    relationship
    Comment in
outcomes validated
false
pmid
37022706
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
e2a283c736ff08655340489dbfb30edbcfdcfd4bbc43d2b928a99a2b79356675
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Jun 1
precision
day
year
2023
publication types
  1. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37022706/
title
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.

Preserved source evidence · Not medical advice